Evidence map›Paper›PMID 33194628›Full record

ArticleFrontiers in oncology2020

Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion.

Zhihua Miao, Tianhao Mu, Longying Liu, Jingjie Rao, Min Jin, Zhizheng Wang, Hui Wang, Chao Lu, Xiaolin Gong, Dongcai Zheng and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhihua MiaoShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
Tianhao MuHaploX Biotechnology, Shenzhen, China.
Longying LiuHaploX Biotechnology, Shenzhen, China.
Jingjie RaoShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
Min JinHaploX Biotechnology, Shenzhen, China.
Zhizheng WangHaploX Biotechnology, Shenzhen, China.
Hui WangHaploX Biotechnology, Shenzhen, China.
Chao LuHaploX Biotechnology, Shenzhen, China.
Xiaolin GongShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
Dongcai ZhengShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
Daoming ZhengShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
Xin LiShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
Yingmei LiHaploX Biotechnology, Shenzhen, China.
Shifu ChenHaploX Biotechnology, Shenzhen, China.
Xinhua ShuShangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine has been getting more attention in lung cancer treatment. Here, we report an unusual case of a 71-year-old Chinese male patient with poorly differentiated lung adenocarcinoma with lymph node metastasis. A 5 years' treatment history of this patient is reported. By serial genetic tests of circulating tumor DNA (ctDNA) from peripheral blood and sediment cell genomic DNA (PE-sDNA) from pleural effusion, a novel chronological combination treatment of icotinib, osimertinib, and crizotinib was adopted for the present genetic mutations, including

Indexed as

ctDNA and PE-sDNAEGFR mutationlung adenocarcinomaMET amplificationserial genetic monitoring

Identifiers

PMID33194628
PMCPMC7645070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.